Comparative performance of SARS CoV-2 lateral flow antigen tests demonstrates their utility for high sensitivity detection of infectious virus in clinical specimens
Preprint
Abstract
Background: Rapid antigen lateral flow devices (LFDs) are set to become a cornerstone of SARS-CoV-2 mass community testing. However, their reduced sensitivity compared to PCR has raised questions of how well they identify infectious cases. Understanding their capabilities and limitations is therefore essential for successful implementation. To address this, we evaluated six commercial LFDs on the same collection of clinical samples and assessed their correlation with infectious virus culture and cycle threshold (Ct) values. Methods: A head-to-head comparison of specificities and sensitivities was performed on six commercial rapid antigen tests using combined nasal/oropharyngeal swabs, and their limits of detection determined using viral plaque forming units (PFU). Three of the LFDs were selected for a further study, correlating antigen test result with RT-PCR Ct values and positive viral culture in Vero-E6 cells. This included sequential swabs and matched serum samples obtained from four infected individuals with varying disease severities. Detection of antibodies was performed using an IgG/IgM Rapid Test Cassette, and neutralising antibodies by infectious virus assay. Finally, the sensitivities of selected rapid antigen LFTs were assessed in swabs with confirmed B.1.1.7 variant, currently the dominant genotype in the UK. Findings: Most of the rapid antigen LFDs showed a high specificity (>98%), and accurately detected 50 PFU/test (equivalent N1 Ct of 23.7 or RNA copy number of 3×10 6 /ml). Sensitivities of the LFDs performed on clinical samples ranged from 65 to 89%. These sensitivities increased in most tests to over 90% for samples with Cts lower than 25. Positive virus culture was achieved for 57 out of 141 samples, with 80% of the positive cultures from swabs with Cts lower than 23. Importantly, sensitivity of the LFDs increased to over 95% when compared with the detection of infectious virus alone, irrespective of Ct. Longitudinal studies of PCR-positive samples showed that most of the tests identified all infectious samples as positive, but differences in test sensitivities can lead to missed cases in the absence of repeated testing. Finally, test performance was not impacted when re-assessed against swabs positive for the dominant UK variant B.1.1.7. Interpretation: In this comprehensive comparison of antigen LFD and virus infectivity, we demonstrate a clear relationship between Ct values, quantitative culture of infectious virus and antigen LFD positivity in clinical samples. Our data support regular testing of target groups using LFDs to supplement the current PCR testing capacity, to rapidly identify infected individuals in situations where they would otherwise go undetected. Funding: King’s Together Rapid COVID-19, Medical Research Council, Wellcome Trust, Huo Family Foundation.Keywords
All Related Versions
- Published version: The Lancet Microbe, 2 (9), e461.
This publication has 22 references indexed in Scilit:
- Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort studyThe Lancet Infectious Diseases, 2021
- Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19The Lancet, 2021
- Rapid coronavirus tests: a guide for the perplexedNature, 2021
- Covid-19: Lateral flow tests miss over half of cases, Liverpool pilot data showBMJ, 2020
- The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in SlovakiamedRxiv, 2020
- Virology, transmission, and pathogenesis of SARS-CoV-2BMJ, 2020
- Prevalence of Asymptomatic SARS-CoV-2 InfectionAnnals of Internal Medicine, 2020
- Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020Eurosurveillance, 2020
- Clinical Course and Molecular Viral Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the Republic of KoreaJAMA Internal Medicine, 2020
- Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic SamplesClinical Infectious Diseases, 2020